Targets › IL7RA
1 program from 1 company in 1 trial: 1 Phase 1; Oncology.
Open in Phaseline: the race on IL7RA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chulalongkorn University | B7H3 specific CAR T cell with IL-7Ra signaling domain Anti-B7H3 CAR-T cell therapy with IL-7 receptor alpha co-stimulatory signaling domain | B7H3, IL7RA | Phase 1 | DIPG Brain Tumor | – |
DIPG Brain Tumor (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.